E65: VC markup dynamics, Russia/US tensions over Ukraine, Altos Labs raises $3B, Stripe mafia & more

Chamath Palihapitiya said his private portfolio was marked up by $1 billion, yet he considered the reported roughly 15% return unreal and believed he was probably flat or down. He said audited marks forced him to recognize other VCs’ higher valuations, exposing how paper gains can diverge sharply from economic reality.

The panel described a structural incentive for venture firms to avoid down rounds because markdowns make the next fund harder to raise. Palihapitiya said he keeps a private “shadow portfolio” at cost basis, but admitted he would care about outside markups if he still needed to raise new funds.

The venture boom was already reversing as crossover investors such as Tiger and Coatue slowed deployment, pulling private-market prices down with them. Sacks said this made new investments more attractive and argued VCs should accept market prices rather than over-negotiate valuation.

On Ukraine, Sacks argued the cleanest de-escalation was for Washington to rule out Ukrainian NATO membership rather than risk an Article 5 commitment against Russia. Sacks and Friedberg treated NATO expansion and Russian security concerns as central to the crisis, while also discussing sanctions and Nord Stream 2 as nonmilitary leverage.

The market discussion focused less on rate hikes themselves than on the danger of tightening rates while draining liquidity from the Fed’s roughly $9 trillion balance sheet. Palihapitiya and Sacks warned that weaker wealth, pricier credit and quantitative tightening could turn inflation-fighting into an avoidable recession.

Friedberg said supply-chain failures were hitting every hardware, biotech and consumer business he was involved with, including U.S.-based companies disrupted by suppliers’ suppliers. He expected surprise revenue misses of 20–30% in some businesses and stressed that rate hikes cannot fix a physical supply constraint.

Altos Labs had raised $3 billion to pursue Yamanaka-factor cellular reprogramming, while Friedberg highlighted mouse work showing younger biomarker profiles without tumors appearing in that experiment. The panel nevertheless questioned whether such enormous upfront capital would outperform smaller, focused teams, with Friedberg still interested in pursuing a leaner competing approach.

The Bolt–Stripe fight looked to the panel more like successful “punch-up” PR than proof that Stripe had blocked Bolt from capital. Sacks admitted he passed on Bolt because its valuation looked roughly twice too high, while Palihapitiya produced a 2015 email showing he also had early access and missed the investment.